Pfizer Presents Positive Data From Phase 2 Study of Ponsegromab in Patients With Cancer Cachexia
Pfizer Presents Positive Data From Phase 2 Study of Ponsegromab in Patients With Cancer Cachexia
輝瑞在癌症消瘦患者中進行的Ponsegromab二期研究發佈了積極數據
- Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at 12 weeks; ponsegromab was generally considered safe and well-tolerated at all dose levelsi
- At the highest dose evaluated, improvements were seen from baseline in appetite and cachexia symptoms, physical activity, and muscle massi
- Based on positive Phase 2 results, registration-enabling studies will start in 2025
- 在全部試驗劑量中，ponsegromab相對安慰劑在體重改變的一級終點達到了研究的主要終點，在12周時達到了最高劑量下5.6%的平均增加；ponsegromab在所有劑量水平下普遍被認爲是安全的、耐受良好的。
- 在最高劑量評估時，相對於基線，食慾和消瘦症狀、身體活動和肌肉質量均有改善。
- 基於積極的2期結果，可用於登記的研究將於2025年開始。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間